All News

TNFinhib.jpg

Biologic Retention in Ankylosing Spondylitis Patients

d Jack Cush, MD

A study of biologic-naïve patients with ankylosing spondylitis (AS) who started therapy with a tumour necrosis factor inhibitor (TNFi) shows that after 5 years only 46% are still on a TNFi and that some are able to lower the dose over time.

Read Article
handcropped.RA_.jpg

Upadacitinib Monotherapy in MTX-IR Rheumatoid Arthritis

d Jack Cush, MD

Upadacitinib (UPA) is an oral, selective JAK1-selective inhibitor being developed for use in rheumatoid arthritis patients; Lancet has reported the SELECT-MONOTHERAPY trial showing that UPA is safe and effective in RA patients with an inadequate response to methotrexate (MTX).

Read Article
glasses-272399_640.jpg

Predictors of Serious Infections with Rituximab

d Jack Cush, MD

The risk of serious infectious events (SIE) with rituximab (RTX) is similar to that seen in other biologics (e.g., RA: 2% or 4.3/100PY), but with prolonged use the risk may change. Recent research says that low IgG levels, RTX induced neutropenia, prior SIE and comorbidities can significantly augment this risk.

A retrospective longitudinal single center study of 700 rheumatic and musculoskeletal diseases (RMDs) treated monitored serum immunoglobulins (at baseline and 4–6 months after each cycle), clinical outcomes and SIE over time.

Read Article
RN.podcast.resized.jpg

RheumNow Podcast – Medical Selfies (5.24.19)

d Jack Cush, MD

Dr. Jack Cush Reviews the news and journal articles from the past week on RheumNow.com

Read Article
obesity.knee_.arthritis.jpg

Additive Effects of Insomnia and Depression on Osteoarthritis

d Jack Cush, MD

A study of osteoarthritis patients, finds that pain is the primary driver for health care utilization, and that the presence of insomnia or depression augments health care use.

Read Article
ACR Clean (Keep)

ACR Statement on CMS Medicare Advantage Final Rule

d Jack Cush, MD

 In August 2018, the CMS announced that Medicare Advantage (MA) plans would be allowed to utilize step therapy for Part B drugs. The American College of Rheumatology (ACR) expressed strong concerns about this proposal.

Read Article
FDA is seeking public input into CBD - cannabidiol - and will be holding a public hearing on CBD this friday May 31st. https://t.co/00MYFNESQ3

Links:

Dr. John Cush RheumNow ( View Tweet)

Risk factors for gouty tophi that ulcerate include: glucocorticoid overuse, tophi duration, and the number of tophi. Based on a chinese study of 105 tophaceous patients of whom 33 developed ulcerations https://t.co/rzYTFCb5jk

Links:

Dr. John Cush RheumNow ( View Tweet)

Research by Robinson and colleagues at Stanford show that mast cell inhibition or depletion significantly improved osteoarthritis in a mouse model. Mast cell driven tryptase increases inflammation, chondrocyte apoptosis, and cartilage breakdown https://t.co/LpgZUhDHvQ

Links:

Dr. John Cush RheumNow ( View Tweet)

Dr. Madelaine Feldman's outstanding lecture on Drug Costs in America: The Bad, the Worse and The Despicable, is available for free at RheumNow Live On Demand at https://t.co/1jGiIQXvua. Check it out - you'll be glad you did. #rheumed #rheum https://t.co/MuNzooK8YB

Links:

Dr. John Cush RheumNow ( View Tweet)
FDA has approved the worlds most expensive drug - $2.1 million - Zolgensma (onasemnogene abeparvovec-xioi), a gene therapy for spinal muscular atrophy (SMA) that affects 1 in 11,000 newborns https://t.co/hHuymQ3sjV

Links:

Dr. John Cush RheumNow ( View Tweet)

Metanalysis suggests leflunomide in psoriatic disease is better at treating arthritis (PsA PsARC 77%) than skin disease (psoriasis PASI50 48% & PASI75 25%). Adverse events in 38% and 15% drop out rate. https://t.co/BIPNtYE6Tr

Links:

Dr. John Cush RheumNow ( View Tweet)

Harvinder S. Luthra, MBBS, Presented with the Albert Nelson Marquis Lifetime Achievement Award by Marquis Who's Who https://t.co/1aTy1axjXL

Links:

Dr. John Cush RheumNow ( View Tweet)

Large UK study shows central adiposity (waist circumference) signify increases risk of psoriasis and rheumatoid arthritis; not PsA. a cross-sectional study of the UK Biobank https://t.co/eKDpUodSR1

Links:

Dr. John Cush RheumNow ( View Tweet)

Lyrica is FDA approved for FM, Neuopathy & adjunctive Rx for partial-onset seizures; but recently failed to meet primary endpoint in a phase III RCT to prevent primary gen tonic-clonic seizures.- but is continuing to develop it for pediatric epilepsy. https://t.co/T9T0Kv1wkP

Links:

Dr. John Cush RheumNow ( View Tweet)

Prospective study of 4796 pts in Osteoarthritis Initiative shows metformin use in obese pts (BMI >30) was Assoc with significantly less medial cartilage loss (0.71% vs. 1.57%/yr) & a trend towards fewer knee replacements over 6 yrs (OR 0.30, p = 0.11) https://t.co/LD0jFWtSLM

Links:

Dr. John Cush RheumNow ( View Tweet)

"The Coach" is the title of my 15-minute TED-like talk at RheumNow Live. I'd like to know what you think. Check it out (for free) by registering for RheumNow Live On Demand https://t.co/1jGiIQXvua #rheumed

Links:

Dr. John Cush RheumNow ( View Tweet)

Study of hematuria in 86 ANCA Associated Vasculitis pts, compared half with & without hematuria after achieving remission from their glomerulonephritis. Hematuria at remission was not assoc w/ ESRD, but with relapse within 44 mos https://t.co/1ld4lOX1ih

Links:

Dr. John Cush RheumNow ( View Tweet)

US National Inpatient study compared 30 912 TKAs in SLE pts vs 8million non-SLE and found SLE had no greater risk for implant infection, implant revision or mortality, but did have more transfusions, longer hosp stay, more Hosp charges https://t.co/LM3dM6KSfc

Links:

Dr. John Cush RheumNow ( View Tweet)

A national database study of 165,748 young females suggest Oral contraceptive use was associated with an 18% (OR 0.82) reduction in anterior cruciate ligament tears. Even lower in 15–19yr olds (OR 0.37). NNT for OCP usage in 15–19 age group was six. https://t.co/If4L5Aq5XJ

Links:

Dr. John Cush RheumNow ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright 2024 All Rights Reserved.

×